Front Barnett Associates LLC cut its position in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 0.3% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,764 shares of the medical research company’s stock after selling 445 shares during the quarter. Thermo Fisher Scientific comprises 4.8% of Front Barnett Associates LLC’s investment portfolio, making the stock its 2nd biggest holding. Front Barnett Associates LLC’s holdings in Thermo Fisher Scientific were worth $26,478,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Bronfman E.L. Rothschild L.P. boosted its position in shares of Thermo Fisher Scientific by 6.4% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 2,719 shares of the medical research company’s stock valued at $474,000 after purchasing an additional 164 shares in the last quarter. Commerce Bank boosted its position in shares of Thermo Fisher Scientific by 1.1% during the second quarter. Commerce Bank now owns 219,079 shares of the medical research company’s stock valued at $38,222,000 after purchasing an additional 2,481 shares in the last quarter. Wesbanco Bank Inc. boosted its position in shares of Thermo Fisher Scientific by 0.9% during the second quarter. Wesbanco Bank Inc. now owns 48,998 shares of the medical research company’s stock valued at $8,549,000 after purchasing an additional 429 shares in the last quarter. Whalerock Point Partners LLC boosted its position in shares of Thermo Fisher Scientific by 2.4% during the second quarter. Whalerock Point Partners LLC now owns 2,866 shares of the medical research company’s stock valued at $500,000 after purchasing an additional 66 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its position in shares of Thermo Fisher Scientific by 43.8% during the second quarter. Principal Financial Group Inc. now owns 806,616 shares of the medical research company’s stock valued at $140,730,000 after purchasing an additional 245,662 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

Several equities research analysts recently weighed in on TMO shares. Deutsche Bank AG set a $200.00 price target on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Saturday, June 10th. BidaskClub lowered Thermo Fisher Scientific from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 27th. Citigroup Inc. restated a “buy” rating and set a $201.00 price target (up from $182.00) on shares of Thermo Fisher Scientific in a research report on Monday, July 10th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $199.00 price target on the stock in a research report on Tuesday, July 11th. Finally, Wells Fargo & Company restated an “outperform” rating and set a $200.00 price target (up from $195.00) on shares of Thermo Fisher Scientific in a research report on Thursday, July 13th. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $202.21.

Shares of Thermo Fisher Scientific Inc (NYSE:TMO) opened at 193.21 on Friday. The company has a market capitalization of $75.37 billion, a P/E ratio of 33.66 and a beta of 1.05. The firm has a 50-day moving average price of $186.68 and a 200 day moving average price of $173.88. Thermo Fisher Scientific Inc has a 12-month low of $139.07 and a 12-month high of $194.30.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, July 26th. The medical research company reported $2.30 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.27 by $0.03. Thermo Fisher Scientific had a return on equity of 15.97% and a net margin of 11.80%. The business had revenue of $5 billion for the quarter, compared to the consensus estimate of $4.92 billion. During the same period last year, the business posted $2.03 EPS. The business’s revenue was up 10.2% compared to the same quarter last year. On average, equities research analysts predict that Thermo Fisher Scientific Inc will post $9.35 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Monday, October 16th. Stockholders of record on Friday, September 15th will be issued a $0.15 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.45%.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.watchlistnews.com/front-barnett-associates-llc-reduces-position-in-thermo-fisher-scientific-inc-tmo/1616845.html.

In other news, VP Seth H. Hoogasian sold 4,140 shares of Thermo Fisher Scientific stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total value of $736,092.00. Following the transaction, the vice president now directly owns 25,518 shares in the company, valued at approximately $4,537,100.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Gregory J. Herrema sold 30,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, August 2nd. The shares were sold at an average price of $176.02, for a total value of $5,280,600.00. Following the completion of the transaction, the senior vice president now owns 67,016 shares in the company, valued at $11,796,156.32. The disclosure for this sale can be found here. Insiders sold a total of 52,738 shares of company stock worth $9,302,112 over the last quarter. Company insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.